Literature DB >> 16144689

The HIF pathway in cancer.

Patrick H Maxwell1.   

Abstract

The transcription factor hypoxia-inducible factor-1 (HIF) is commonly activated in cancer. This has major effects on gene expression, and is important in tumor angiogenesis. Besides being activated by low oxygen, genetic events in cancer contribute to activating HIF. Most striking is that loss of function of the VHL tumour suppressor protein results in constitutive activation of the HIF pathway. An important aim is to define the contribution of HIF activation to the evolution of different cancers, and its potential as a therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16144689     DOI: 10.1016/j.semcdb.2005.03.001

Source DB:  PubMed          Journal:  Semin Cell Dev Biol        ISSN: 1084-9521            Impact factor:   7.727


  57 in total

1.  Genome-wide identification and annotation of HIF-1α binding sites in two cell lines using massively parallel sequencing.

Authors:  Kousuke Tanimoto; Katsuya Tsuchihara; Akinori Kanai; Takako Arauchi; Hiroyasu Esumi; Yutaka Suzuki; Sumio Sugano
Journal:  Hugo J       Date:  2011-02-19

2.  The aryl hydrocarbon receptor nuclear translocator (Arnt) is required for tumor initiation by benzo[a]pyrene.

Authors:  Shengli Shi; Diana Y Yoon; Kimberly C Hodge-Bell; Ilona G Bebenek; Michael J Whitekus; Ruixue Zhang; Alistair J Cochran; Sara Huerta-Yepez; Sun-Hee Yim; Frank J Gonzalez; Anil K Jaiswal; Oliver Hankinson
Journal:  Carcinogenesis       Date:  2009-09-15       Impact factor: 4.944

Review 3.  Hypoxia--implications for pharmaceutical developments.

Authors:  Lucas Donovan; Scott M Welford; John Haaga; Joseph LaManna; Kingman P Strohl
Journal:  Sleep Breath       Date:  2010-07-14       Impact factor: 2.816

4.  Six degrees of separation: the oxygen effect in the development of radiosensitizers.

Authors:  Bryan T Oronsky; Susan J Knox; Jan Scicinski
Journal:  Transl Oncol       Date:  2011-08-01       Impact factor: 4.243

Review 5.  Kidney cancer pathology in the new context of targeted therapy.

Authors:  Yves Allory; Stéphane Culine; Alexandre de la Taille
Journal:  Pathobiology       Date:  2011-06-14       Impact factor: 4.342

6.  Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor.

Authors:  Xun Xu; Yong Hou; Xuyang Yin; Li Bao; Aifa Tang; Luting Song; Fuqiang Li; Shirley Tsang; Kui Wu; Hanjie Wu; Weiming He; Liang Zeng; Manjie Xing; Renhua Wu; Hui Jiang; Xiao Liu; Dandan Cao; Guangwu Guo; Xueda Hu; Yaoting Gui; Zesong Li; Wenyue Xie; Xiaojuan Sun; Min Shi; Zhiming Cai; Bin Wang; Meiming Zhong; Jingxiang Li; Zuhong Lu; Ning Gu; Xiuqing Zhang; Laurie Goodman; Lars Bolund; Jian Wang; Huanming Yang; Karsten Kristiansen; Michael Dean; Yingrui Li; Jun Wang
Journal:  Cell       Date:  2012-03-02       Impact factor: 41.582

7.  A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors.

Authors:  Quincy Siu-Chung Chu; Randeep Sangha; Jennifer Spratlin; Larissa J Vos; John R Mackey; Alexander J B McEwan; Peter Venner; Evangelos D Michelakis
Journal:  Invest New Drugs       Date:  2015-03-13       Impact factor: 3.850

8.  Regulation of membrane-type 4 matrix metalloproteinase by SLUG contributes to hypoxia-mediated metastasis.

Authors:  Chi-Hung Huang; Wen-Hao Yang; Shyue-Yih Chang; Shyh-Kuan Tai; Cheng-Hwei Tzeng; Jung-Yie Kao; Kou-Juey Wu; Muh-Hwa Yang
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

9.  Cytoglobin is upregulated by tumour hypoxia and silenced by promoter hypermethylation in head and neck cancer.

Authors:  R J Shaw; M M Omar; S Rokadiya; F A Kogera; D Lowe; G L Hall; J A Woolgar; J Homer; T Liloglou; J K Field; J M Risk
Journal:  Br J Cancer       Date:  2009-07-07       Impact factor: 7.640

10.  Inhibition of hypoxia-inducible factor-1alpha (HIF-1alpha) protein synthesis by DNA damage inducing agents.

Authors:  Jessica Jie Wei Lou; Yee Liu Chua; Eng Hui Chew; Jie Gao; Martin Bushell; Thilo Hagen
Journal:  PLoS One       Date:  2010-05-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.